INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 140 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2017. The put-call ratio across all filers is 1.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $174,000 | -73.6% | 14,100 | -66.6% | 0.01% | -77.3% |
| Q3 2021 | $660,000 | +1550.0% | 42,260 | +185.5% | 0.02% | +2100.0% |
| Q2 2021 | $40,000 | -59.2% | 14,800 | -86.3% | 0.00% | -66.7% |
| Q4 2020 | $98,000 | -76.6% | 108,300 | -11.4% | 0.00% | -85.7% |
| Q3 2020 | $418,000 | -83.0% | 122,300 | -87.5% | 0.02% | -84.4% |
| Q2 2020 | $2,457,000 | +7578.1% | 981,427 | +7508.0% | 0.14% | +6650.0% |
| Q1 2020 | $32,000 | -99.7% | 12,900 | -99.6% | 0.00% | -99.7% |
| Q4 2019 | $12,193,000 | +1561.2% | 3,196,600 | +84.7% | 0.67% | +1032.2% |
| Q3 2019 | $734,000 | +280.3% | 1,731,100 | +746.1% | 0.06% | +293.3% |
| Q2 2019 | $193,000 | – | 204,600 | +888.4% | 0.02% | – |
| Q4 2018 | $0 | -100.0% | 20,700 | -68.4% | 0.00% | -100.0% |
| Q3 2017 | $338,000 | +11166.7% | 65,566 | +111.5% | 0.02% | – |
| Q2 2017 | $3,000 | -94.2% | 31,000 | -2.8% | 0.00% | -100.0% |
| Q1 2017 | $52,000 | -77.4% | 31,900 | -35.9% | 0.00% | -62.5% |
| Q3 2016 | $230,000 | – | 49,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |